UNSPSC 51343002: Nevirapine

This classification denotes a reverse transcriptase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99DK7FVK1H. European Medicines Agency schedules Nevirapine, anhydrous in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25191. Nevirapine generally arises in the molecular formula C15H14N4O. The term NEVIRAPINE is a European Pharmacopoeia designation. NEVIRAPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule nevirapine under HS 29339940 and SITC 51577. As of Q4 2014, NEVIRAPINE remains the US FDA Preferred Term for this commodity. Nevirapine bears US NLM identifiers UMLS ID C0132326 and NCI Concept Code C29277. SMILES: O=C1[NH]C2C(N(C3CC3)C3NCCCC13)NCCC2C.

UNSPSC 51343002 Nevirapine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The code's abstract definition—an antiretroviral pharmaceutical used in HIV treatment—does not correspond to the recent opportunities posted under it. Seminole County, Florida issued an IFB on June 30, 2026 for naloxone (opioid-reversal medication) and drug deactivation systems, neither of which are nevirapine or antiretroviral drugs. The City of Tampa solicited medical and first aid supplies for its fire rescue division through an IFB due March 13, 2026, encompassing respiratory equipment, cardiac monitoring devices, and medical consumables unrelated to nevirapine or HIV treatment. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription programs with pharmacy benefit managers and wholesalers, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, neither of which explicitly targets nevirapine procurement. The mismatch between the code's nominal pharmaceutical scope and the actual work being solicited under it suggests either systematic miscoding or that this code's recent activity does not reflect genuine nevirapine purchasing patterns in state and local government.

Geographic activity spanning the opportunities above includes Florida (Seminole County), Texas (HHS Commission), Minnesota (MMCAP), and by extension participating states in the MMCAP cooperative network including Oregon. However, none of the recent opportunities represent nevirapine-specific demand. If pursuing this code, clarify with prospective customers whether procurement activity under 51343002 is expected to change or whether nevirapine solicitations are tagged under alternative UNSPSC codes in your target jurisdictions.